
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
METHODS article
Front. Pharmacol.
Sec. Pharmacogenetics and Pharmacogenomics
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1548991
This article is part of the Research Topic Use of Bioinformatics in Pharmacogenetics to Optimize Drug Efficacy View all 8 articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The sequencing of the human genome in 2003 marked a transformative shift from a onesize-fits-all approach to personalized medicine, emphasizing patient-specific molecular and physiological characteristics. Advances in sequencing technologies, from Sanger methods to Next-Generation Sequencing (NGS), have generated vast genomic datasets, enabling the development of tailored therapeutic strategies. Pharmacogenomics (PGx) has played a pivotal role in elucidating how the genetic make-up influences inter-individual variability in drug efficacy and toxicity discovering predictive and prognostic biomarkers.However, challenges persist in interpreting polymorphic variants and translating findings into clinical practice. Multi-omics data integration and bioinformatics tools are essential for addressing these complexities, uncovering novel molecular insights, and advancing precision medicine. In this review, starting from our experience in PGx studies performed by DMET microarray platform, we propose a guideline combining machine learning, statistical, and network-based approaches to simplify and better understand complex DMET PGx data analysis which can be adapted for broader PGx applications, fostering accessibility to highperformance bioinformatics, also for non-specialists. Moreover, we describe an example of how bioinformatic tools can be used for a comprehensive integrative analysis which could allow the translation of genetic insights into personalized therapeutic strategies.
Keywords: pharmacogenomic, Genomic data analysis, BioInformatic, Pathway, Network analysis
Received: 20 Dec 2024; Accepted: 05 Mar 2025.
Copyright: © 2025 Arbitrio, Milano, Lucibello, Emanuela, Staropoli, Tassone, Tagliaferri, Cannataro and Agapito. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Mariamena Arbitrio, CNR, Catanzaro, Italy
Marianna Milano, Magna Græcia University, Catanzaro, Italy
Giuseppe Agapito, Magna Græcia University, Catanzaro, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.